Q-omics provides the consensus-scored CCDC28B profile across patient tissues and cancer cell-line models. CCDC28B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC28B is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CCDC28B RNA expression shows 17,917 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where CCDC28B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC28B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC28B survival associations across molecular data types. CCDC28B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC28B RNA expression–survival associations across cancer types. High CCDC28B expression shows unfavorable associations in KIRC, MESO, UCS, BLCA and LIHC, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC28B RNA expression.
This table summarizes CCDC28B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC28B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC28B shows higher tumor expression in COAD, LIHC, KICH, LUSC, ESCA and LUAD. The COAD box plot shows higher CCDC28B RNA expression in tumor versus normal tissue (log2 FC = +1.029, t-test p < 0.001).
This table shows molecular features associated with CCDC28B in patient tissues and cancer cell lines. In patient samples, CCDC28B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC28B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
